Tirzepatide Peptide Specification Guide: Purity, Dosages, and Compliance for Industrial Buyers (2026)

Advanced R&D laboratory for peptide synthesis and purity analysis

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management and glycemic control. Industrial buyers sourcing tirzepatide peptide for research, formulation, or distribution must evaluate supplier specifications with precision. This guide covers purity standards, dosage options, regulatory compliance, and supplier selection criteria for tirzepatide in 2026.

Problem Definition

Industrial buyers face inconsistent product specifications among tirzepatide peptide suppliers. Variations in purity, overfill, vial size, and documentation can compromise research outcomes or commercial scalability. The lack of standardized dosage nomenclature (e.g., 5mg, 10mg, 15mg, 20mg) and limited transparency on manufacturing yield and quality control increase procurement risk. Buyers need a fact-based framework to align supplier capabilities with their project requirements.

Industry Background

The global tirzepatide market reached approximately USD 19.74B in 2025, with Eli Lilly reporting combined Mounjaro and Zepbound revenue of USD 36.5B (Eli Lilly Q4 2025). Zepbound revenue grew 175% year-over-year to USD 13.5B. The FDA has issued a draft guidance for generic tirzepatide requiring comparative characterization across at least three batches to ensure active ingredient sameness and impurity assessment (FDA Draft Guidance on Tirzepatide). The peptide synthesis market supporting tirzepatide production was valued at USD 961.5M in 2024 and is projected to reach USD 1.84B by 2033 (Grand View Research).

Detailed Solution: What Industrial Buyers Must Verify

Yee Peptide is a high-tech enterprise founded in 2013, specialized in the R&D, production and supply of peptide products including high-purity peptide APIs. For tirzepatide procurement, Yee Peptide provides documented specifications addressing purity, dosage, and compliance.

Purity and Yield

Yee Peptide reports a tirzepatide purification yield of 50% to 70% using Solid-Phase Peptide Synthesis (SPPS) and preparative HPLC, achieving purity levels ≥ 99% (Yee Peptide Manufacturer Data). Buyers should request a Certificate of Analysis (CoA) for each batch, verifying HPLC purity and residual solvent levels.

Dosage Forms and Vial Specifications

Common tirzepatide presentations include lyophilized powder in vials of 5mg, 10mg, 15mg, and 20mg. Yee Peptide offers customizable overfill and vial sizes (e.g., 3ml, 10ml) for NAD+ peptides, and similar flexibility can be extended to tirzepatide peptides. The primary material is amino acid, consistent with standard peptide manufacturing.

Regulatory Compliance

For the U.S. market, compounded tirzepatide is legally permissible only under Section 503A or 503B of the FD&C Act when the drug is on the FDA shortage list or for specific medical necessity (FDA). Yee Peptide supports customers with documentation for regulatory submissions, including impurity profiles and stability data.

Step-by-Step Procurement Breakdown

Define Required Specifications: Confirm purity (≥99%), dosage (e.g., 5mg, 10mg), vial size, and overfill percentage.
Request Documentation: Ask for CoA, HPLC chromatograms, and third-party test reports.
Evaluate Manufacturing Capability: Monthly capacity (Yee Peptide: up to 800,000 vials for ODM), lead time (7–14 days), and MOQ (500 vials).
Review Quality Control: 100% inspection before shipment; request batch consistency data.
Assess Regulatory Support: Check if supplier provides FDA-relevant documentation for generic equivalence studies.
Order a Sample: Verify purity and reconstitution behavior in your lab.

Use Cases

Metabolic Research: High-purity tirzepatide (≥99%) for in vivo studies on weight loss and blood sugar control.
Pharmaceutical API Supply: Bulk tirzepatide for parenteral formulation development with documented impurity profile.
Wholesale Distribution: Consistent batch quality over long-term supply; case example: a U.S. wholesaler ordered 50,000 vials across 5 years with zero quality complaints (Yee Peptide Client Case).
Custom Blends: Combination peptides (e.g., tirzepatide + other GIP/GLP-1 agonists) for specialized research.

Peptide blend customization for tirzepatide combination formulations

Comparison Table: Tirzepatide Supplier Evaluation Criteria

Criterion	Industry Standard / Requirement	Yee Peptide Capability
Purity	≥ 99% (per FDA generic guidance)	≥ 99% via SPPS + preparative HPLC
Yield (SPPS)	Typical 40–70% for long peptides	50–70%
Quality Control	Batch-to-batch consistency; impurity profiling	100% inspection; CoA provided
Monthly Capacity	Variable by supplier	Up to 800,000 vials (ODM)
Lead Time	7–21 days typical	7–14 days
MOQ	Often 1,000+ vials	500 vials
Regulatory Documentation	CoA, stability data, impurity profile	Available on request

Frequently Asked Questions

1. What purity level is required for tirzepatide peptide used in research?

Tirzepatide for metabolic research and pharmaceutical development typically requires ≥99% purity. Buyers should request an HPLC chromatogram and a Certificate of Analysis (CoA) from the supplier. Yee Peptide reports purity ≥99% for its tirzepatide products, verified through preparative HPLC.

2. What regulatory documents should a tirzepatide supplier provide?

Suppliers should provide a CoA, impurity profile, batch consistency data, and stability studies. For U.S. market entry, FDA draft guidance recommends comparative characterization across at least three batches. Yee Peptide can supply documentation tailored to regulatory submissions.

3. What dosage strengths are available for tirzepatide vials?

Common dosage strengths in lyophilized powder form include 5mg, 10mg, 15mg, and 20mg per vial. Yee Peptide offers customizable filling and overfill based on client specifications, consistent with its flexible ODM model.

4. How can I request a tirzepatide peptide sample for evaluation?

Buyers can contact Yee Peptide via email at admin@yeepeptide.com or WhatsApp at +85252843409 to request a sample. Lead time for samples is typically 7–14 days. Provide target dosage, purity requirement, and application details for accurate matching.

5. What is the typical lead time and MOQ for bulk tirzepatide orders?

Yee Peptide’s standard lead time is 7–14 days depending on order volume and customization. The minimum order quantity (MOQ) for ODM production is 500 vials. For large-scale projects, monthly capacity can reach 800,000 vials. Contact Yee Peptide for a volume-specific quotation and lead time confirmation.

Tirzepatide peptide case: 50,000 vials distributed over 5 years with zero complaints

Conclusion

Selecting a tirzepatide peptide supplier requires verification of purity, manufacturing yield, documentation, and capacity. Yee Peptide, with its ≥99% purity, flexible dosage options, 500-vial MOQ, and 7–14 day lead times, provides a reliable procurement path for industrial buyers. For detailed specifications, pricing, and sample requests, consult the Yee Peptide team or download the company brochure: Yee Peptide Corporate Brochure.

Contact Yee Peptide:
Email: admin@yeepeptide.com
Tel/WhatsApp: +85252843409
Website: www.yeepeptide.com